Rebamipide as a remedy for prevention and treatment of gastro- and enteropathy related to antiplatelets, anticoagulants and NSAIDs therapy


DOI: https://dx.doi.org/10.18565/therapy.2020.5.206-220

Vorobyova N.M., Tkacheva O.N.

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia – ASS «Russian gerontological scientific and clinical center», Moscow
The review article examines the problem of the prevention and treatment of gastro- and enteropathy – adverse processes from the gastrointestinal tract associated with antiplatelet therapy, anticoagulants and non-steroidal anti-inflammatory drugs (NSAIDs) therapy, as well as the problem of their severe complications - gastrointestinal bleeding.
The necessity of prescribing gastro- and enteroprotectors (in particular, rebamipide) to protect mucous membranes of the stomach and intestines from the damaging effects of abovementioned drugs is discussed. The results of clinical trials, demonstrating the possibilities of taking rebamipide for the treatment and prevention of gastro- and enteropathy in comparison with other gastroprotectors and placebo are considered. Rebamipide has been shown to be a unique medicine combining the properties of both gastro- and enteroprotectors recommended by Russian experts to protect the mucous membranes of the stomach, small and large intestines in patients taking NSAIDs, including acetylsalicylic acid.
Keywords: gastropathy, enteropathy, gastroenteroprotector, rebamipid, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, direct-acting oral anticoagulants, proton pump inhibitors, gastrointestinal bleeding
Read entire article

Literature


  1. Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther. 2000; 7(2): 115–21. doi: 10.1097/00045391-200007020-00008.

  2. Оганов Р.Г., Симаненков В.И., Бакулин И.Г. с соавт. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика, 2019; 1: 5–66. [Oganov R.G., Simanenkov V.I., Bakulin I.G. et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Kardiovasculyarnaya terapiya i profilaktika. 2019; 1: 5–66. (In Russ.)]. doi: https://doi.org/10.15829/1728-8800-2019-1-5-66.

  3. Harirforoosh S., Asghar W., Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci, 2013; 16(5): 821–47. doi: 10.18433/J3VW2F.

  4. Roth S.H. Nonsteroidal anti-inflammatory drug gastropathy. We started it – can we stop it? Arch Intern Med. 1986; 146(10): 1075–76.

  5. van Soest E.M., Valkhoff V.E., Mazzaglia G. et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut. 2011; 60(12): 1650–59. doi: 10.1136/gut.2011.239848.

  6. Лазебник Л.Б., Голованова Е.В., Алексеенко С.А. с соавт. Рекомендации по профилактике и лечению эзофагогастроэнтероколопатий, индуцированных нестероидными противовоспалительными препаратами. Экспериментальная и клиническая гастроэнтерология, 2018; 3: 4–18 [Lazebnik L.B., Golovanova E.V., Alekseenko S.A., Bakulina N.V., Baranovsky A.Yu., Belova G.V. et al. Recommendations for the prevention and treatment of esophagogastro-entero-colopathy induced by nonsteroidal antiinflammatory drugs «NSAID». Eksperimental'naya i klinicheskaya gastroenterologiya. 2018; 3: 4–18 (In Russ.)].

  7. Freedberg D.E., Kim L.S., Yang Y.X. The Risks and Benefits of Long-term use of proton pump inhibitors: Expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017; 152(4): 706–15. doi: 10.1053/j.gastro.2017.01.031.

  8. Xie Y., Bowe B., Li T. et al. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017; 7(6): e015735. doi: 10.1136/bmjopen-2016-015735.

  9. Shiraev T.P., Bullen A. Proton pump inhibitors and cardiovascular events: A systematic review. Heart Lung Circ. 2018; 27(4): 443–50. doi: 10.1016/j.hlc.2017.10.020.

  10. Maggio M., Corsonello A., Ceda G.P. et al. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med. 2013; 173(7): 518–23. doi: 10.1001/jamainternmed.2013.2851.

  11. Naito Y., Yoshikawa T., Yoshida N., Kondo M. Role of oxygen radical and lipid peroxidation in indomethacin-induced gastric mucosal injury. Dig Dis Sci. 1998; 43(9 Suppl.): 30S–34S.

  12. Naito Y., Iinuma S., Yagi N. et al. Prevention of Indomethacin-induced gastric mucosal injury in Helicobacter pylori-negative healthy volunteers: a comparison study rebamipide vs famotidine. J Clin Biochem Nutr. 2008; 43(1): 34–40. doi: 10.3164/jcbn.2008041.

  13. Kim H.K., Kim J.I., Kim J.K. et al. Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. Dig Dis Sci, 2007; 52(8): 1776–82. doi: 10.1007/s10620-006-9367-y.

  14. Ono S., Kato M., Imai A. et al. Preliminary trial of rebamipide for prevention of low-dose aspirin-induced gastric injury in healthy subjects: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Biochem Nutr. 2009; 45(2): 248–53. doi: 10.3164/jcbn.09-24.

  15. Hasegawa M., Horiki N., Tanaka K. et al. The efficacy of rebamipide add-on therapy in arthritic patients with COX-2 selective inhibitor-related gastrointestinal events: a prospective, randomized, open-label blinded-endpoint pilot study by the GLORIA study group. Mod Rheumatol. 2013; 23(6): 1172–78. doi: 10.1007/s10165-012-0819-2.

  16. Park S.H., Cho C.S., Lee O.Y. et al. Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: A randomized, multicenter, controlled trial STORM STUDY. J Clin Biochem Nutr. 2007; 40(2): 148–55. doi: 10.3164/jcbn.40.148.

  17. Kim J.H., Park S.H., Cho C.S. et al. Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity. Gut Liver. 2014; 8(4): 371–79. doi: 10.5009/gnl. 2014.8.4.371.

  18. Tozawa K., Oshima T., Okugawa T. et al. A randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel. Dig Dis Sci. 2014; 59(8): 1885–90. doi: 10.1007/s10620-014-3108-4.

  19. Pittayanon R., Piyachaturawat P., Rerknimitr R. et al. Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial. J Gastroenterol Hepatol. 2019; 34(9): 1517–22. doi: 10.1111/jgh.14671.

  20. Yamamoto T., Isono A., Mishina Y. et al. Gastroduodenal mucosal injury in patients taking low-dose aspirin and the role of gastric mucoprotective drugs: possible effect of rebamipide. J Clin Biochem Nutr. 2010; 47(1): 27–31. doi: 10.3164/jcbn.09-103.

  21. Takeuchi K., Takayama S., Hashimoto E. et al. Effect of rebamipide on gastric bleeding and ulcerogenic responses induced by aspirin plus clopidogrel under stimulation of acid secretion in rats. J Gastroenterol Hepatol. 2014; 29(Suppl 4): 37–46. doi: 10.1111/jgh.12774.

  22. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. с соавт. Ассоциация ревматологов России, Российское общество по изучению боли, Российская гастроэнтерологическая ассоциация, Российское научное медицинское общество терапевтов, Ассоциация травматологов-ортопедов России, Российская ассоциация паллиативной медицины. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология, 2018; 56 (Прил. 1): 1–29 [Karateev A.E., Nasonov E.L., Ivashkin V.T. et al; Association of Rheumatologists of Russia, Russian Society for the Study of Pain, Russian Gastroenterology Association, Russian Scientific Medical Society of Therapists, Association of Traumatologists and Orthopedists of Russia, Russian Association of Palliative Medicine. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-prakticheskaya revmatologiya. 2018; 56(Suppl. 1): 1–29 (In Russ.)].

  23. Taki M., Oshima T., Tozawa K. et al. Analysis of risk factors for colonic diverticular bleeding and recurrence. Medicine (Baltimore). 2017; 96(38): e8090. doi: 10.1097/MD.0000000000008090.

  24. Nagata N., Niikura R., Yamada A. et al. Acute middle gastrointestinal bleeding risk associated with NSAIDs, antithrombotic drugs, and PPIs: A multicenter case-control study. PLoS One. 2016; 11(3): e0151332. doi: 10.1371/journal.pone.0151332.

  25. Goldstein J.L., Eisen G.M., Lewis B. et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther. 2007; 25(10): 1211–22. doi: 10.1111/j.1365-2036.2007.03312.x.

  26. Hawkey C.J., Ell C., Simon B. et al. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin Gastroenterol Hepatol. 2008; 6(5): 536–44. doi: 10.1016/j.cgh.2007.12.023.

  27. Watanabe T., Sugimori S., Kameda N. et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: A pilot study. Clin Gastroenterol Hepatol. 2008; 6(11): 1279–82. doi: 10.1016/j.cgh.2008.06.021.

  28. Iwamoto J., Mizokami Y., Saito Y. et al. Small-bowel mucosal injuries in low-dose aspirin users with obscure gastrointestinal bleeding. World J Gastroenterol. 2014; 20(36): 13133–38. doi: 10.3748/wjg.v20.i36.13133.

  29. Maiden L., Thjodleifsson B., Theodors A. et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005; 128(5): 1172–78.

  30. Lai Y., Zhong W., Yu T. et al. Rebamipide promotes the regeneration of aspirin-induced small-intestine mucosal injury through accumulation of β-catenin. PLoS One. 2015; 10(7): e0132031. doi: 10.1371/journal.pone.0132031.

  31. Nishida U., Kato M., Nishida M. et al. Evaluation of small bowel blood flow in healthy subjects receiving low-dose aspirin. World J Gastroenterol. 2011; 17(2): 226–30. doi: 10.3748/wjg.v17.i2.226.

  32. Mizukami K., Murakami K., Abe T. et al. Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol. 2011; 17(46): 5117–22. doi: 10.3748/wjg.v17.i46.5117.

  33. Kurokawa S., Katsuki S., Fujita T. et al. A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol. 2014; 49(2): 239–44. doi: 10.1007/s00535-013-0805-2.

  34. Watanabe T., Takeuchi T., Handa O. et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin induced moderate-to-severe small intestinal damage. PLoS One. 2015; 10(4): e0122330. doi: 10.1371/journal.pone.0122330.

  35. Zhang S., Qing Q., Bai Y. et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. 2013; 58(7): 1991–2000. doi: 10.1007/s10620-013-2606-0.

  36. Лазебник Л.Б., Ткаченко Е.И., Абдулганиева Д.И. с соавт. VI национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacter pylori заболеваний (VI московские соглашения). Экспериментальная и клиническая гастроэнтерология, 2017; 2: 3–21 [Lazebnik L.B., Tkachenko E.I., Abdulganieva D.I. et al. VI National guidelines for the diagnosis and treatment of acid-dependent and Helicobacter pylori-associated diseases (VI Moscow Accords). Eksperimental’naya I klinicheskaya gastroenterologia. 2017; 2: 3–21 (In Russ.)].

  37. Tai F.W.D., McAlindon M.E. NSAIDs and the small bowel. Curr Opin Gastroenterol. 2018; 34(3): 175–82. doi: 10.1097/MOG.0000000000000427.

  38. Washio E., Esaki M., Maehata Y. et al. Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug induced small bowel injury: A randomized, placebo-controlled trial. Clin Gastroenterol Hepatol. 2016; 14(6): 809–15.e1. doi: 10.1016/j.cgh.2015.10.022.

  39. Syer S.D., Blackler R.W., Martin R. et al. NSAID enteropathy and bacteria: a complicated relationship. J Gastroenterol. 2015; 50(4): 387–93. doi: 10.1007/s00535-014-1032-1.

  40. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139–51. doi: 10.1056/NEJMoa0905561.

  41. Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883–91. doi: 10.1056/NEJMoa1009638.

  42. Giugliano R.P., Ruff C.T., Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22): 2093–104. doi: 10.1056/NEJMoa1310907.

  43. Ruff C.T., Giugliano R.P., Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383: 955–62. doi: 10.1016/S0140-6736(13)62343-0.

  44. Kolb J.M., Flack K.F., Chatterjee-Murphy P. et al. Locations and mucosal lesions responsible for major gastrointestinal bleeding in patients on warfarin or dabigatran. Dig Dis Sci. 2018; 63(7): 1878–89. doi: 10.1007/s10620-018-5007-6.

  45. Sherwood M.W., Nessel C.C., Hellkamp A.S. et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial. J Am Coll Cardiol. 2015; 66(21): 2271–81. doi: 10.1016/j.jacc.2015.09.024.

  46. Miller C.S., Dorreen A., Martel M. et al. Risk of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017; 15(11): 1674–83.e3. doi: 10.1016/j.cgh.2017.04.031.

  47. Cheung K.S., Leung W.K. Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management. World J Gastroenterol. 2017; 23(11): 1954–63. doi: 10.3748/wjg.v23.i11.1954.

  48. Chan E.W., Lau W.C., Leung W.K. et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: A population-based study. Gastroenterology. 2015; 149(3): 586–95.e3. doi: 10.1053/j.gastro.2015.05.002.

  49. Maruyama K., Yamamoto T., Aoyagi H. et al. Difference between the upper and the lower gastrointestinal bleeding in patients taking nonvitamin K oral anticoagulants. Biomed Res Int. 2018; 2018: 7123607. doi: 10.1155/2018/7123607.

  50. Youn S.H., Lim H., Ju Y. et al. Effect of gastroprotective agents on upper gastrointestinal bleeding in patients receiving direct oral anticoagulants. Scand J Gastroenterol. 2018; 53(12): 1490–95. doi: 10.1080/00365521.2018.1541478.

  51. Yamashita T., Watanabe E., Ikeda T. et al. Observational study of the effects of dabigatran on gastrointestinal symptoms in patients with non-valvular atrial fibrillation. J Arrhythm. 2014; 30: 478–84. https://doi.org/10.1016/j.joa.2014.02.011.

  52. Bytzer P., Connolly S.J., Yang S. et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol. 2013; 11(3): 246–52.e1-5. doi: 10.1016/j.cgh.2012.10.021.


About the Autors

Natalya M. Vorobyova, MD, head of the laboratory of cardiovascular aging of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia – ASS «Russian gerontological scientific and clinical center». Address: 129226, Moscow, 16 1st Leonov Str. Tel.: +7 (915) 192-22-78. Email: natalyavorobjeva@mail.ru
Olga N. Tkacheva, MD, professor, director of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia – ASS «Russian gerontological scientific and clinical center». Address: 129226, Moscow, 16 1st Leonova Str. E-mail: tkacheva@rgnkc.ru

Back to Content

Бионика Медиа